$1.03+0.01 (+0.98%)
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
Cocrystal Pharma, Inc. in the Healthcare sector is trading at $1.03 with a market capitalization of $15M. Wall Street consensus targets $9.00 (2 analysts), implying a +773.8% move over the next 12 months. The stock is currently near its 52-week low of $0.86, remaining 8.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $225,000 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.36M↑ | -$2.48M↓ | -$2.09M↑ | -$2.11M↑ | -$2.34M |
| Net Income | -$2.30M↑ | -$2.43M↓ | -$2.05M↑ | -$2.06M↑ | -$2.30M |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create a...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
td class="col-issue">Next Technology Holding Inc.
US stocks look set to open little changed in Friday's trading session ahead of consumer sentiment da